Ona Therapeutics, a Metrix Partners client, closed a €30M Series A in June 2020. Existing investor Asabys Partners took part, together with new investors Alta Life Sciences, Bpifrance through its InnoBio 2 fund, Fund+ and Ysios Capital.

About Ona Therapeutics
Ona Therapeutics is a Barcelona biotech company focused on discovering and developing therapeutic biologics to treat metastatic cancer. Metastasis, the spread of cancer to other organs, causes most cancer deaths, yet few treatments target it directly. Ona’s approach aims at first-in-class treatments for metastatic cancer patients.
The Series A
According to the company’s press release, the financing is intended to take the lead candidate to proof of clinical efficacy. The syndicate combined Spanish, French and Belgian life sciences investors, giving the company a strong European base. The round was also announced by Ysios Capital.
Ona joined the Metrix client list in 2019, when it raised €1.5M from Sabadell Asabys. The Series A was a large step up within a year.
Metrix Partners and Ona Therapeutics
Metrix supports Ona as a client. Finance for a clinical-stage biotech covers:
- Budgets and cash planning by development milestone.
- Management of public grants and loans alongside venture funding.
- Reporting to a syndicate of several investors.
- Contracts with research organisations and their accounting.
- Preparation for future financing and partnering.
Five lessons for biotech founders raising a Series A
- Fund to a clear milestone. The Series A should reach a value inflection point, such as clinical proof of concept.
- Build a balanced syndicate. Investors from several countries bring networks and capacity for follow-on rounds.
- Plan for delays. Preclinical and clinical timelines often slip. The budget should include contingency.
- Use non-dilutive funding. Spanish and EU programmes can extend runway and reduce dilution.
- Keep reporting consistent. Several investors and funders need one reliable set of numbers.
What biotech founders should prepare
- A development plan with milestones, costs and timelines.
- A summary of IP, licences and freedom to operate.
- A list of public funding with conditions and repayments.
- Monthly accounts reconciled to the statutory filings.
- A cap table and summary of all financing instruments.
The Spanish biotech ecosystem
Barcelona has become one of Europe’s active biotech hubs, with research centres, hospitals and specialist investors such as Ysios, Asabys and Alta Life Sciences. Rounds of €30M for an early-stage company were rare in Spain a few years earlier. Larger syndicates with international funds have made them possible, and they allow companies to reach clinical milestones without having to move abroad.
Metrix Partners in life sciences
Metrix has worked with life sciences clients including Accure Therapeutics, Northern Biologics, Aelix Therapeutics and DeepUll.






